MarketPeel
Insider Trading Intelligence
Pricing
…
SR

Simrat Randhawa

DNTH
CHIEF MEDICAL OFFICER · DIANTHUS THERAPEUTICS, INC. /DE/ · CIK 0001992260
FILING MIX · LIFETIME49%/51%
BUYS
20
SELLS
21
TOTAL VALUE
$16.71M
COMPANIES
1
ACTIVE SINCE
Sep 2023
HOLDINGS NOW
64,276
AVG SELL PX
$48.81
TRADE KIND
SHOWING 41 / 41
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 11 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Simrat Randhawa, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+42.86%+6.88%-1.84%+8.72%+4.40%—
14d7+0.00%+9.16%+0.02%+9.14%+5.96%—
30d7+0.00%+7.96%+0.43%+7.54%+9.75%—
60d7+0.00%+3.33%+5.03%-1.69%+6.57%—
90d7+0.00%+8.93%+5.74%+3.18%+14.84%—
180d7(1 pending)+33.33%+123.64%+13.70%+109.94%+116.13%—
1y7(5 pending)+100.00%+111.27%+33.66%+77.61%+77.61%—
2y7(5 pending)+100.00%+181.06%+57.48%+123.58%+123.58%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
DNTH · 64,276 shares · as of Jun 1, 2026
037,50075,000112,500150,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 20 buys / 21 sellsCOVERAGE · 12 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
16,943$90.72$1.54M8,159Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
4,159$91.37$380.0K4,000Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
9,375——96,875Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
5,428$89.72$487.0K25,102Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
3,998$8.44$33.7K7,998Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
3,998——0Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
9,375$22.07$206.9K30,530Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
6,249——47,925Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
6,908$17.88$123.5K14,906Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
6,249$21.77$136.0K21,155Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
6,908——64,276Jun 1, 2026Jun 2, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
12,500——106,250Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
7,998$8.44$67.5K7,998Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
7,998——3,998Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
8,332$21.77$181.4K21,330Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
12,500$22.07$275.9K33,830Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
8,332——54,174Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
33,830$81.48$2.76M0Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
5,000$17.88$89.4K12,998Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
5,000——71,184Mar 12, 2026Mar 13, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
150,000——150,000Feb 3, 2026Feb 4, 2026 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
37,494$21.77$816.2K81,781Nov 14, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
40,287——76,184Nov 14, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
31,250——118,750Nov 14, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
31,250$22.07$689.7K113,031Nov 14, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
40,287$17.88$720.3K44,287Nov 14, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
37,494——62,506Nov 14, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
109,031$38.14$4.16M4,000Nov 14, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
83,978$8.44$708.8K87,978Nov 13, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
18,576$37.72$700.7K4,000Nov 13, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Head of R&D
3,529$17.88$63.1K91,507Nov 13, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
26,166$35.80$936.7K65,341Nov 13, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
3,529——116,471Nov 13, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
42,765$37.04$1.58M22,576Nov 13, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, Head of R&D
83,978——11,996Nov 13, 2025Nov 14, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
60,000——60,000Sep 23, 2025Sep 25, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
150,000——150,000Feb 3, 2025Feb 4, 2025 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
100,000——100,000May 23, 2024May 28, 2024 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
120,000——120,000Jan 24, 2024Jan 26, 2024 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
Chief Medical Officer
2,000$13.20$26.4K4,000Sep 22, 2023Sep 25, 2023 ↗View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
Chief Medical Officer
2,000$13.20$26.4K2,000Sep 21, 2023Sep 25, 2023 ↗View →
Other insiders · DNTH
Loading peer insiders…
About this filer
CIK 0001992260
ROLE
CHIEF MEDICAL OFFICER
PRIMARY
DNTH
COMPANIES
1
ACTIVE SINCE
Sep 2023
MARKETPEEL · /INSIDER/0001992260DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback